Clinical Trial Documentation & Compliance Support for a Major Biopharma Organisation

Context

A large biopharma organisation needed structured regulatory documentation support for clinical-trial-related materials intended for submittal by the client to the U.S. Food and Drug Administration (FDA).

Overview

We prepared the strategic plan and supporting documentation end-to-end for the client’s use. The client remained the party of record for submission and agency interactions.

Approach

1. Clarify document purpose, audience and source evidence with RA stakeholders
2. Author and structure the plan and related writing so technical and clinical inputs form one narrative
3. Iterate with the client’s team on data integrity and risk-aware documentation practices
4. Support the client through to a submission-ready package

Our role

• Translated complex clinical data and technical processes into structured regulatory writing for the client’s use
• Emphasised data integrity and risk-aware documentation practices
• Documentation and strategy partner to the client’s regulatory affairs team — not the sponsor of record and not the FDA

Result

We prepared the plan from start to finish. The client submitted it to the FDA, and the plan was approved by the FDA. This describes FDA acceptance of that plan — not FDA clearance or approval of a marketed product, and not a partnership with FDA.

Boundaries

• Client remained party of record with the agency
• No partnership with FDA; outcome stated for this engagement’s plan only — not a guarantee of future decisions
• Described anonymously under our case-study policy

Related

Regulatory support · Biotech & pharma · How we work